Establish Early Development Strategies For Therapeutics Proteins
Wednesday, October 21, 2020 10:00 am (EST)
The protein therapeutics field has expanded considerably in number and diversity of protein formats. Along come higher expectations for patient-centric products. And the clinical and regulatory landscapes are ever-evolving. All these have significant implications for the early CMC development strategies for protein products.
In this webinar we explore early-phase development strategies, covering both fundamentals (successful approaches such as platforms) and specialized considerations (what to consider when faced with novel constructs) as follows:
- drivers for the early-phase development strategy, and challenges typically encountered at this stage
- previously-established successful strategies for early-phase development
- desirable tools and expertise to enable early-phase development
- transforming our perceptions of early-phase risks into innovation opportunities
Aura: Particle and aggregate quantification, characterization, ID, and full USP 788 testing
Wednesday, October 28, 2020 8:00 am (PT)
Learn how the Aura system can be a complete tool for your lab’s stability testing and quality control measurements. With the ability to quantify aggregates and particles, identify them as inherent, intrinsic, or extrinsic, and perform analysis with any volume you choose the Aura offers continuity of method like no other instrument can. Perform early stage analysis with very little volume and use the same instrument to perform large volume particle counts in your entire container.